OBJECTIVE: Bromelain, a clinically used pineapple extract and natural product, has reported anti-inflammatory and immunomodulatory activities. The purpose of this study was to determine the effect of bromelain treatment in an ovalbumin (OVA)-induced murine model of allergic airway disease (AAD). METHODS: To establish AAD, mice were sensitized with intraperitoneal (i.p.) OVA/alum and challenged with daily OVA aerosols. Mice were treated i.p. with either saline, 2 or 6 mg/kg bromelain, twice daily for four consecutive days. Bronchoalveolar lavage leukocytes and cytokines, lung histology, airway hyperresponsiveness, and lymphocyte populations via flow cytometry were compared between groups. RESULTS: Bromelain treatment of AAD mice resulted in reduced total BAL leukocytes, eosinophils, CD4+ and CD8+ T lymphocytes, CD4+/CD8+ T cell ratio, and IL-13. CONCLUSION: Bromelain attenuated development of AAD while altering CD4+ to CD8+ T lymphocyte populations. The reduction in AAD outcomes suggests that bromelain may have similar effects in the treatment of human asthma and hypersensitivity disorders.
OBJECTIVE: Bromelain, a clinically used pineapple extract and natural product, has reported anti-inflammatory and immunomodulatory activities. The purpose of this study was to determine the effect of bromelain treatment in an ovalbumin (OVA)-induced murine model of allergic airway disease (AAD). METHODS: To establish AAD, mice were sensitized with intraperitoneal (i.p.) OVA/alum and challenged with daily OVA aerosols. Mice were treated i.p. with either saline, 2 or 6 mg/kg bromelain, twice daily for four consecutive days. Bronchoalveolar lavage leukocytes and cytokines, lung histology, airway hyperresponsiveness, and lymphocyte populations via flow cytometry were compared between groups. RESULTS: Bromelain treatment of AAD mice resulted in reduced total BAL leukocytes, eosinophils, CD4+ and CD8+ T lymphocytes, CD4+/CD8+ T cell ratio, and IL-13. CONCLUSION: Bromelain attenuated development of AAD while altering CD4+ to CD8+ T lymphocyte populations. The reduction in AAD outcomes suggests that bromelain may have similar effects in the treatment of humanasthma and hypersensitivity disorders.
Authors: C M Schramm; L Puddington; C A Yiamouyiannis; E G Lingenheld; H E Whiteley; W W Wolyniec; T C Noonan; R S Thrall Journal: Am J Respir Cell Mol Biol Date: 2000-02 Impact factor: 6.914
Authors: Manar A Nader; Mohammed S El-Awady; Asem A Shalaby; Dina S El-Agamy Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-06-26 Impact factor: 3.000
Authors: Mary L Cardeccia; Lindsay H Elam; Kelly A Deabold; Erin L Miscioscia; Janice L Huntingford Journal: Can Vet J Date: 2022-01 Impact factor: 1.008
Authors: Eric R Secor; Anurag Singh; Linda A Guernsey; Jeff T McNamara; Lijun Zhan; Nilanjana Maulik; Roger S Thrall Journal: Int Immunopharmacol Date: 2009-01-20 Impact factor: 4.932
Authors: Eric R Secor; Steven M Szczepanek; Anurag Singh; Linda Guernsey; Prabitha Natarajan; Karim Rezaul; David K Han; Roger S Thrall; Lawrence K Silbart Journal: Evid Based Complement Alternat Med Date: 2012-10-02 Impact factor: 2.629